Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.

Tumori - 1 Jan 2000

Liu Zhe-Bin, Wu Jiong, Ping Bo, Feng Li-Qing, Di Gen-Hong, Lu Jin-Song, Shen Kun-Wei, Shen Zhen-Zhou, Shaol Zhi-Min

Abstract excerpt

AIMS AND BACKGROUND: To evaluate the immunohistochemical characterization of CK5/6 and CK17 and whether the expression level of the two markers was correlated with clinical outcome or pathological feature in triple negative (ER-, PR-, HER-2-) patients with breast cancer. METHODS AND STUDY DESIGN: We carried out an immunohistochemical assay for CK5/6 and CK17 markers on formalin-fixed invasive carcinoma samples...

Topics

Age Factors
Biomarkers, Tumor
Breast Neoplasms
Disease-Free Survival
Female
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Keratin-17
Keratin-5
Keratin-6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Lymphatic Metastasis

Menopause

Neoplasm Staging

Phenotype

Source

Identifiers

PMID: 19366057
DOI: 10.1177/030089160909500110

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.PMID 19366057Read ↗

Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer.Semantic proximity Read ↗

Prognostic relevance of basal cytokeratin expression in operable breast cancer.Semantic proximity Read ↗

Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers.Semantic proximity Read ↗

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.Semantic proximity Read ↗

Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.Semantic proximity Read ↗

Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.Semantic proximity Read ↗

[Basal-like breast cancers: clinicopathological features and outcome].Semantic proximity Read ↗

Prognostic markers in triple-negative breast cancer.Semantic proximity Read ↗

c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.Semantic proximity Read ↗

Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.Semantic proximity Read ↗

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.Semantic proximity Read ↗

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.